Skye Bioscience (SKYE) Income from Continuing Operations (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Income from Continuing Operations of 12509361.0 for Q1 2026, down 12.66% year-over-year from 14323136.86 in Q1 2025, and up 13.38% quarter-over-quarter from 14441963.0 in Q4 2025.
Skye Bioscience (SKYE) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Income from Continuing Operations for 15 consecutive years, with 12509361.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 12.66% year-over-year to 12509361.0; the TTM figure through Mar 2026 stood at 57330856.0 (down 75.59% YoY), while the FY2025 annual figure was 55924814.0, down 110.5% from the prior year.
- Income from Continuing Operations improved to 12509361.0 in Q1 2026 per SKYE's latest filing, from 14441963.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3043399.0 in Q1 2022 and bottomed at 24945834.0 in Q3 2023.
- Historically, Income from Continuing Operations has averaged 8948687.29 across 5 years, with a median of 7902816.0 in 2024.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations slumped 697.68% — and 2024, when it surged 84.37%.
- Skye Bioscience's Income from Continuing Operations stood at 9891642.0 in 2022, then jumped by 55.32% to 4419930.0 in 2023, then sank by 120.51% to 9746479.0 in 2024, then tumbled by 48.18% to 14441963.0 in 2025, then climbed by 13.38% to 12509361.0 in 2026.
- Business Quant data shows SKYE's Income from Continuing Operations at 12509361.0 in Q1 2026, 14441963.0 in Q4 2025, and 12754660.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | -10.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.51 Mn |
| Dec 31, 2025 | -14.44 Mn |
| Sep 30, 2025 | -12.75 Mn |
| Jun 30, 2025 | -17.62 Mn |
| Mar 31, 2025 | -11.10 Mn |
| Dec 31, 2024 | -9.75 Mn |
| Sep 30, 2024 | -3.90 Mn |
| Jun 30, 2024 | -7.90 Mn |
| Mar 31, 2024 | -5.02 Mn |
| Dec 31, 2023 | -4.42 Mn |
| Sep 30, 2023 | -24.95 Mn |
| Jun 30, 2023 | -3.11 Mn |
| Mar 31, 2023 | -5.17 Mn |
| Dec 31, 2022 | -9.89 Mn |
| Sep 30, 2022 | -3.13 Mn |
| Jun 30, 2022 | -3.42 Mn |
| Mar 31, 2022 | -3.04 Mn |
| Dec 31, 2021 | -2.51 Mn |
| Sep 30, 2021 | -1.82 Mn |
| Jun 30, 2021 | -2.02 Mn |